Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Hypertension |
Dose: Tablet – 5 mg Frequency: once daily Note: Usual starting dose. In some patients, 2.5 mg may be an appropriate starting dose. If the antihypertensive effect of 5 mg is inadequate, the dose may be increased to 10 mg and then, if necessary, to 20 mg once daily. |
|
Indication: Heart failure |
Dose: Tablet – 1.25 mg Frequency: once daily (in the morning) Duration: for 1 week Note: Initially 1.25 mg, then if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5 mg once daily for 4 weeks, then 10 mg once daily. Maximum 10 mg daily. |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment greater than 40 mL/min |
Dose: Dose adjustment not necessary Note: Dose adjustment not necessary |
|
Condition: Renal Impairment less than 40 mL/min |
Dose: 2.5 mg/day Frequency: once daily Note: 2.5 mg/day initially; titrate slowly and monitor |
Administration
- Can be taken with or without food
- Take at same time each day
Side Effect
- Dizziness (10%)
- Dyssomnia (8%-10%)
- Bradyarrhythmia (9%)
- Upper respiratory infection (5%)
- Diarrhea (4%)
- Rhinitis (4%)
- Arthralgia (3%)
- Cough (3%)
- Dyspnea (2%)
- Nausea (2%)
- Pharyngitis (2%)
- Sinusitis (2%)
- Vomiting (2%)
- Cold extremities
- Hypotension
- Depression
- Dyspepsia
- Bronchospasm
- Aggravate CHF
- Decrease HDL
- Hypertriglyceridemia
- Mask symptoms of hypoglycemia
- Decreased exercise tolerance
- Raynaud's phenomenon
- May increase triglyceride levels and insulin resistance
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone)
|
May potentiate AV conduction time and increase negative inotropic effect
|
|
Catecholamine-depleting Drugs (specific agents that deplete catecholamines) (e.g. reserpine, guanethidine)
|
May produce excessive sympathetic activity
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Cardiogenic Shock
|
Risk of cardiovascular collapse
|
|
Overt Cardiac Failure
|
Risk of worsening heart failure
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Keep in a dry place away from light and heat. Keep out of the reach of children.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.